July 29, 2018 – By Margaret Staats
Baker Bros Advisors Lp increased its stake in Chemocentryx Inc. (CCXI) by 743.85% based on its latest 2018Q1 regulatory filing with the SEC. Baker Bros Advisors Lp bought 364,965 shares as the company’s stock rose 32.26% while stock markets declined. The hedge fund held 414,029 shares of the health care company at the end of 2018Q1, valued at $5.63M, up from 49,064 at the end of the previous reported quarter. Baker Bros Advisors Lp who had been investing in Chemocentryx Inc. for a number of months, seems to be bullish on the $558.84 million market cap company. The stock decreased 8.53% or $1.06 during the last trading session, reaching $11.37. About 162,714 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since July 29, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx
Morgens Waterfall Vintiadis & Co Inc decreased its stake in Unitedhealth Group Inc (UNH) by 28.17% based on its latest 2018Q1 regulatory filing with the SEC. Morgens Waterfall Vintiadis & Co Inc sold 4,200 shares as the company’s stock rose 4.65% while stock markets declined. The hedge fund held 10,712 shares of the medical specialities company at the end of 2018Q1, valued at $2.29M, down from 14,912 at the end of the previous reported quarter. Morgens Waterfall Vintiadis & Co Inc who had been investing in Unitedhealth Group Inc for a number of months, seems to be less bullish one the $245.96B market cap company. The stock decreased 0.41% or $1.05 during the last trading session, reaching $255.95. About 1.66M shares traded. UnitedHealth Group Incorporated (NYSE:UNH) has risen 37.57% since July 29, 2017 and is uptrending. It has outperformed by 25.00% the S&P500. Some Historical UNH News: 17/04/2018 – UnitedHealth 1Q Net $2.84B; 04/04/2018 – UnitedHealthcare Launches Step Up for Better Health Sweepstakes with GHR to Encourage Walking and Support Boys & Girls Clubs; 14/03/2018 – Zachary Tracer: SCOOP: UnitedHealth is no longer interested in a deal for Envision or its surgery centers. Comes after Envision; 13/03/2018 – UNITEDHEALTH GROUP INC – WITTY WILL STEP DOWN FROM UNITEDHEALTH GROUP BOARD OF DIRECTORS, EFFECTIVE IMMEDIATELY; 11/05/2018 – MOODY’S ASSIGNS BAA3 RATINGS TO DAVITA’S SENIOR SECURED TERM LOAN ADD-ONS; 02/04/2018 – Humana, MultiPlan, Optum, Quest, UnitedHealth Launch Blockchain Pilot Program; 24/05/2018 – UnitedHealth: LabCorp to Continue as UnitedHealth’s Exclusive National Laboratory Provider Until Jan. 1, 2019; 29/05/2018 – Molina Healthcare Elects Richard Zoretic to Board of Directors; 11/04/2018 – Online therapy start-up Talkspace hires a chief medical officer from UnitedHealth; 12/04/2018 – Former UnitedHealth Group Executives Join Talkspace – Neil Leibowitz, MD, JD as Chief Medical Officer; Deb Adler as Senior VP, Network and Quality
Among 7 analysts covering ChemoCentryx (NASDAQ:CCXI), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. ChemoCentryx had 9 analyst reports since September 3, 2015 according to SRatingsIntel. On Tuesday, March 13 the stock rating was maintained by JP Morgan with “Overweight”. On Tuesday, August 8 the stock rating was maintained by Cowen & Co with “Hold”. Zacks downgraded the stock to “Sell” rating in Monday, September 21 report. JMP Securities initiated ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, February 21 with “Mkt Outperform” rating. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Buy” rating given on Thursday, August 10 by JMP Securities. The firm has “Sell” rating by Zacks given on Thursday, September 3.
Baker Bros Advisors Lp, which manages about $8.20B and $11.80B US Long portfolio, decreased its stake in Ablynx Nv by 1.98 million shares to 2.18M shares, valued at $118.77M in 2018Q1, according to the filing. It also reduced its holding in Ovid Therapeutics Inc. by 85,600 shares in the quarter, leaving it with 247,733 shares, and cut its stake in Progenics Pharmaceuticals Inc. (NASDAQ:PGNX).
Since May 1, 2018, it had 0 buys, and 12 sales for $7.89 million activity. Another trade for 100 shares valued at $1,410 was sold by KANAYA SUSAN M. Another trade for 10,857 shares valued at $152,028 was made by Schall Thomas J. on Thursday, June 28.
Investors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It turned negative, as 10 investors sold CCXI shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. Prelude Cap Management Ltd Liability Corporation owns 983 shares. 45,740 are held by Keybank Association Oh. Connor Clark Lunn Invest Management reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Arrowstreet Limited Partnership holds 0% or 34,216 shares. Renaissance Tech Ltd Liability Corporation stated it has 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). State Of Wisconsin Invest Board reported 19,000 shares. Td Asset Mgmt has 20,300 shares for 0% of their portfolio. Carmignac Gestion invested in 0.04% or 390,097 shares. National Bank Of America De invested in 85,137 shares. Rhumbline Advisers holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 23,578 shares. Tiaa Cref Invest Mgmt invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Legal & General Gru Pcl stated it has 4,583 shares. Employees Retirement Systems Of Ohio owns 117,524 shares or 0.01% of their US portfolio. Jane Street Gru Lc holds 0% or 14,429 shares in its portfolio. Acadian Asset Ltd Llc owns 521,864 shares for 0.03% of their portfolio.
Morgens Waterfall Vintiadis & Co Inc, which manages about $187.68 million and $131.52M US Long portfolio, upped its stake in On Semiconductor Corp (ONNN) by 54,770 shares to 149,770 shares, valued at $3.66M in 2018Q1, according to the filing. It also increased its holding in Royal Dutch Shell Plc by 12,500 shares in the quarter, for a total of 20,292 shares, and has risen its stake in Editas Medicine Inc.
More notable recent UnitedHealth Group Incorporated (NYSE:UNH) news were published by: Fool.com which released: “Why Omnicom, UnitedHealth Group, and Goldman Sachs Slumped Today” on July 17, 2018, also Fool.com with their article: “Here’s What UnitedHealth Investors Should Be Watching” published on July 19, 2018, Nasdaq.com published: “Lyfebulb and UnitedHealth Group Announce Winners of the 2018 Innovation Challenge for Patient Entrepreneurs” on July 26, 2018. More interesting news about UnitedHealth Group Incorporated (NYSE:UNH) were released by: Bizjournals.com and their article: “UnitedHealth may bid for Tenet health-management unit; deal could fetch $2B” published on July 19, 2018 as well as 247Wallst.com‘s news article titled: “Microsoft Adds to Lead as Dow’s Top-Performing Stock” with publication date: July 28, 2018.
Since January 31, 2018, it had 0 insider buys, and 11 insider sales for $28.49 million activity. Another trade for 202 shares valued at $47,959 was made by Shine Kenneth Irwin on Thursday, April 19. 22,184 shares were sold by RENFRO LARRY C, worth $5.08M. $2.38M worth of stock was sold by HOOPER MICHELE J on Wednesday, January 31. WILENSKY GAIL R sold $779,001 worth of stock or 3,090 shares. $3.28M worth of stock was sold by Nelson Steven H on Thursday, March 15.
Among 27 analysts covering UnitedHealth Group (NYSE:UNH), 26 have Buy rating, 0 Sell and 1 Hold. Therefore 96% are positive. UnitedHealth Group had 94 analyst reports since September 2, 2015 according to SRatingsIntel. Deutsche Bank maintained the shares of UNH in report on Thursday, July 13 with “Buy” rating. The company was downgraded on Monday, June 11 by Credit Suisse. The stock of UnitedHealth Group Incorporated (NYSE:UNH) earned “Overweight” rating by Morgan Stanley on Wednesday, June 7. Piper Jaffray initiated the stock with “Overweight” rating in Wednesday, January 4 report. Jefferies maintained it with “Buy” rating and $280.0 target in Friday, January 12 report. The firm has “Buy” rating by Bernstein given on Wednesday, April 18. Cantor Fitzgerald maintained the shares of UNH in report on Wednesday, June 7 with “Buy” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Tuesday, June 27 report. The company was maintained on Thursday, August 17 by Morgan Stanley. Mizuho maintained it with “Buy” rating and $20000 target in Tuesday, July 18 report.
Analysts await UnitedHealth Group Incorporated (NYSE:UNH) to report earnings on October, 16. They expect $3.30 earnings per share, up 24.06% or $0.64 from last year’s $2.66 per share. UNH’s profit will be $3.17B for 19.39 P/E if the $3.30 EPS becomes a reality. After $3.14 actual earnings per share reported by UnitedHealth Group Incorporated for the previous quarter, Wall Street now forecasts 5.10% EPS growth.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.